Evidence map›Paper›PMID 42837819›Full record

ArticleThe journal of physiological sciences : JPS2026

Exogenous pyruvate protects IMS32 Schwann cells from impairing the maturation process under hyperglycemia.

Hideji Yako, Sana Hattori, Sayaka Iwamoto, Tatsuya Ooki, Waraku Nagatani, Yuika Kaburaki, Yuki Miyamoto, Kazunori Sango, Junji Yamauchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of physiological sciences : JPS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hideji YakoLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan; Laboratory for Drug Target Discovery, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan. Electronic address: hyako@toyaku.ac.jp.
Sana HattoriLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan; Laboratory for Drug Target Discovery, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
Sayaka IwamotoLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan; Laboratory for Drug Target Discovery, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
Tatsuya OokiLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan; Laboratory for Drug Target Discovery, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
Waraku NagataniLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan; Laboratory for Drug Target Discovery, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
Yuika KaburakiLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan; Laboratory for Drug Target Discovery, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
Yuki MiyamotoLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan; Laboratory for Drug Target Discovery, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Okura, Setagaya, Tokyo, 157-8535, Japan.
Kazunori SangoBrain Metabolic Regulation Group Frontier Laboratory, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan.
Junji YamauchiLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan; Laboratory for Drug Target Discovery, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 192-0392, Japan; Department of Biological Science, Tokyo College of Biotechnology, Kitakojiya, Oota, Tokyo, 144-0032, Japan. Electronic address: yamauchi@toyaku.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peripheral neuropathy is a chronic common complication of diabetes mellitus. Continuous hyperglycemia induces metabolic disturbances and elicits oxidative stress. However, the impact of hyperglycemia on the maturation of Schwann cells is not fully understood. Therefore, we examined whether hyperglycemia affects the maturation process of IMS32 Schwann cells treated with forskolin, a Schwann cell maturation enhancer, using promoter assays and immunoblotting of Schwann cell markers such as MBP, CNPase, and GFAP. IMS32 cells exposed to high-glucose conditions showed decreased expression of these markers. Exogenous pyruvate plays a crucial role in maintaining glucose metabolism and reducing oxidative stress under hyperglycemic conditions. These decreases were prevented by pyruvate supplementation. Pyruvate treatment also prevented IMS32 cells from producing reactive oxygen species and from impairing mitochondrial membrane potential. These results indicate that hyperglycemia impairs Schwann cell maturation accompanied by mitochondrial dysfunction and oxidative stress, contributing to the development and progression of diabetic peripheral neuropathy.

Indexed as

Exogenous pyruvateHyperglycemiaMaturationOxidative stressSchwann cells

Identifiers

PMID42837819
PMCPMC13672852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.